Form 4: Actinium Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
Sandesh Seth, Chief Executive Officer and a Director of Actinium Pharmaceuticals, Inc., reported multiple transactions in common stock on September 2, 2026.
Summary
- Grant/award: acquired 753,600 Common Stock on September 2, 2026; holds 938,081 after (Direct).
- Grant/award: acquired 1,027,274 Common Stock on September 2, 2026; holds 1,965,355 after (Direct).
- Grant/award: acquired 1,130,400 Stock Option (Right to Buy) on September 2, 2026; holds 1,130,400 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sandesh Seth — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-02 | Grant/award | Common Stock | 753,600 | — | — | 938,081 |
| 2026-09-02 | Grant/award | Common Stock | 1,027,274 | — | — | 1,965,355 |
| 2026-09-02 | Grant/award | Stock Option (Right to Buy) | 1,130,400 | — | — | 1,130,400 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-02 | Grant/award (753,600 shares) |
| 2026-09-02 | Grant/award (1,027,274 shares) |
| 2026-09-02 | Grant/award (1,130,400 shares) |
Keywords
insider transaction, Form 4, ATNM, Actinium Pharmaceuticals, Inc., neutral, Sandesh Seth
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.